14 completed, 10 active not recruiting, 1 approved for marketing, 1 withdrawn. 16 Phase 1, 8 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 14, Active not recruiting 2 |
| Phase 2 | 8 | Active not recruiting 7, Withdrawn 1 |
| Phase 3 | 3 | Active not recruiting 3 |
Follow Loxo-292: new trials by email Literature Review of Loxo-292 trials Research Report on Loxo-292
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants Rosuvastatin, Selpercatinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 28 | 2023-07-27 | 2025-09-16 |
| Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer Carboplatin, Pemetrexed, Selpercatinib - Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | SWOG Cancer Research Network | 2022-07-25 | 2024-07-09 | |
| A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Loxo Oncology, Inc. | 46 | 2022-04-19 | 2025-03-21 |
| A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Selpercatinib, Placebo - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Eli Lilly and Company | 152 | 2021-12-20 | 2026-03-04 |
| A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Loxo Oncology, Inc. | 42 | 2021-12-03 | 2025-03-17 |
| A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Loxo Oncology, Inc. | 224 | 2021-10-29 | 2025-03-17 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-02-26 | 2026-05-20 |
| Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) Selpercatinib - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Active not recruiting | SWOG Cancer Research Network | 124 | 2020-04-08 | 2026-03-23 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Selpercatinib - Solid Tumor, Medullary Thyroid Cancer | Phase 2 | Active not recruiting | Eli Lilly and Company | 77 | 2020-03-16 | 2026-08-07 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Selpercatinib, Carboplatin, Cisplatin - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | Eli Lilly and Company | 261 | 2020-02-17 | 2026-10-21 |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer Selpercatinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 291 | 2020-02-11 | 2026-03-19 |
| Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants Selpercatinib, Ranitidine, Omeprazole - Healthy | Phase 1 | Completed | Eli Lilly and Company | 20 | 2019-07-08 | 2024-10-30 |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 36 | 2019-06-13 | 2026-01-06 |
| A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants Selpercatinib, Moxifloxacin, Placebo - Healthy | Phase 1 | Completed | Eli Lilly and Company | 32 | 2019-04-16 | 2025-09-18 |
| A Study of Selpercatinib (LY3527723) in Healthy Participants Selpercatinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 18 | 2019-02-12 | 2025-05-18 |
| A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants Repaglinide, Selpercatinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 16 | 2019-01-29 | 2025-12-11 |
| A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function Selpercatinib - Healthy, Renal Insufficiency | Phase 1 | Completed | Eli Lilly and Company | 37 | 2018-12-19 | 2025-09-18 |
| A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants Selpercatinib - Healthy, Hepatic Impairment | Phase 1 | Completed | Eli Lilly and Company | 36 | 2018-12-10 | 2025-04-13 |
| A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants [14C]-Selpercatinib, Selpercatinib - Healthy | Phase 1 | Completed | Eli Lilly and Company | 12 | 2018-08-01 | 2025-04-23 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (8) · Carcinoma, Medullary (6) · Lung Neoplasms (4) · Thyroid Cancer, Papillary (4) · Thyroid Neoplasms (4) · Breast Neoplasms (3) · Central Nervous System Neoplasms (3) · Colonic Neoplasms (3) · Sarcoma (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Ependymoma (2) · Glioma (2)
Eli Lilly and Company (17) · Loxo Oncology, Inc. (4) · National Cancer Institute (NCI) (2) · SWOG Cancer Research Network (2) · M.D. Anderson Cancer Center (1)
United States (23) · Australia (8) · Canada (6) · France (6) · Germany (6) · Italy (6) · Japan (6) · Spain (6) · Israel (5) · Singapore (5) · South Korea (5) · United Kingdom (5) · China (4) · Hong Kong (4) · Poland (4)
Yasir Y Elamin (2) · Andrea T Franson (1) · Donald W Parsons (1) · Mark Zafereo (1)
PMID 36657661, PMID 32846060, PMID 32846061, PMID 33150799, PMID 33591402, PMID 34088726, PMID 34292174, PMID 35353553, PMID 35378489, PMID 35923928, PMID 35930972, PMID 35950566, PMID 35969032, PMID 36062046, PMID 36108661, PMID 36122315, PMID 36996322, PMID 37265412, PMID 37315261, PMID 37655205, PMID 37870969, PMID 37870973, PMID 37934000, PMID 38661071, PMID 38828957, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39694978, PMID 39759832, PMID 39983053, PMID 40617171, PMID 41166674, PMID 41996652, PMID 42223087, PMID 42686334, PMID 42867148, PMID 42874021
2019 (3), 2023 (2), U10CA180886 (2), U10CA180888 (2), 2017 (1)